The latest update puts LTM’s fair value at ₹5,951.97, compared with the prior ₹6,219.67. This comes alongside an analyst price target that has shifted from US$53 to US$58 after the recent selloff.
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced its abstract has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results